Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma

Blood

Volumn 96, Issue 10, 2000, Pages 3544-3552

  Honeychurch, J ^a   Tutt, A L ^a   Valerius, T ^a   Heijnen, I A F M ^a   Van de Winkel, J G J ^a   Glennie, M J ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD64 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; BISPECIFIC ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN G;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; B CELL LYMPHOMA; CELL ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; IMMUNITY; LYMPHOMA CELL; MOUSE; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CALCIUM SIGNALING; CANCER TRANSPLANTATION; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LEUKOCYTE ACTIVATION; METABOLISM; PATHOLOGY; STANDARD;

ANIMALS; ANTIBODIES, BISPECIFIC; CALCIUM SIGNALING; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULIN G; IMMUNOTHERAPY; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEUTROPHIL ACTIVATION; RECEPTORS, IGG; T-LYMPHOCYTES;

EID: 0034668385     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.10.3544.h8003544_3544_3552     Document Type: Article

References (47)

1. An overview of monoclonal antibody therapy of cancer
2. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
3. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
4. Signaling antibodies in cancer therapy
5. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein
6. Monoclonal antibodies as agonists: An expanded role for their use in cancer therapy
7. Monoclonal antibody therapy of B cell lymphoma: Signaling activity on tumor cells appears more important than recruitment of effectors
8. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
9. Fc receptors
10. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
11. Bispecific antibodies in cancer therapy
12. Clinical significance of IgG receptors and FcγR-directed immunotherapies
13. Preclinical studies with FcγR bispecific antibodies and G-CSF primed neutrophils as effector cells against HER-2/neu overesxpressing breast cancer
14. Clinical evaluation of the bispecific antibody MDX-H210 (anti-HER-2/ neu x anti-FcγRI) in combination with G-CSF (filgrastim) for treatment of advanced breast cancer
15. A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses the HER2/neu
16. Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody re sponses in transgenic mice
17. Generation of HER-2/neu-specific cytotoxic neutrophils (PMN) in vivo
18. Spontaneous murine B cell leukemia
19. Characterisation of a new B cell lymphoma
20. 2 antibody
21. Radioimmunotherapy of B cell lymphoma: The importance of antibody specificity in determining successful treatment of established disease
22. 1, act primarily with heavy chain determinants
23. Self renewal of B-1 lymphocytes is dependent on CD19
24. Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function
25. The induction of skingraft tolerance in MHC-mismatched or primed recipients: Primed T-cells can be tolerized in the periphery with CD4 and CD8 antibodies
26. 3 antibody derivatives
27. 2 antibody containing thioether-linked Fab' fragments
28. Neutrophils express the high affinity receptor for IgG (FcγRI; CD64) after in vivo application of rhG-CSF
29. Editorial: Guidelines On the analysis of tumor rates and death rates in experimental animals
30. Identification and characterisation of the routine homolog CD22, a lymphocyte B-restricted adhesion molecule
31. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
32. Bispecific Ab therapy of B-cell lymphoma: Target cell specificity of antibody derivatives appears critical in determining therapeutic outcome
33. 1 lymphoma: Increased efficacy with multiple injections and CD28 induced co-stimulation
34. Mechanisms of antigen receptor dependent apoptosis of human B lymphoma cells probed with a panel of 27 monoclonal antibodies
35. Emergence of immunoglobulin variants following treatment of a B-cell leukemia with an immunotoxin composed of anti-idiotype and saporin
36. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulation
37. Recombinant human granulocyte colony-stimulating factor inhibits the metastasis of hematogenous and non-hematogenous tumors in mice
38. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
39. Treatment of murine B cell lymphoma with bispecific monoclonal antibody (anti-idiotype x anti-CD3)
40. Analysis of the interaction of monoclonal antibodies with surface IgM on neoplastic B-cells
41. Cancer dormancy: Role of cyclin dependent kinase inhibitots in induction of cell cycle arrest mediated via membrane IgM
42. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
43. The FcγRIA (CD64) ligand binding chain triggers major histocompatability complex class II antigen presentation independently of its associated FcR γ-chain
44. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help
45. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
46. Univalent antibodies kill tumor cells in vitro and in vivo
47. The development of anti-CD79 monoclonal antibodies for treatment of B-cell neoplastic disease